Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
oleh: Ken Saijo, Ken Saijo, Hiroo Imai, Hiroo Imai, Kota Ouchi, Kota Ouchi, Keiju Sasaki, Keiju Sasaki, Yuya Yoshida, Yuya Yoshida, Yoshifumi Kawamura, Yoshifumi Kawamura, Sakura Taniguchi, Sakura Taniguchi, Yuki Kasahara, Yuki Kasahara, Keigo Komine, Keigo Komine, Hidekazu Shirota, Hidekazu Shirota, Masanobu Takahashi, Masanobu Takahashi, Chikashi Ishioka, Chikashi Ishioka
Format: | Article |
---|---|
Diterbitkan: | Frontiers Media S.A. 2023-08-01 |
Deskripsi
BackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear.MethodsThis study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients’ characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed.ResultsThe 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and −9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= −0.41, p=0.0017; PFS: r=−0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤−45 was associated with better OS and PFS.ConclusionDpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.